➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Moodys
McKesson
AstraZeneca
Dow

Last Updated: August 5, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BRAFTOVI

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Braftovi

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03898908 ↗ Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain Not yet recruiting MFAR Clinical Research S.L. Phase 2 2019-05-01 Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain. Cohort 1 will include patients with asymptomatic brain metastases and cohort 2 will include patients with symptomatic brain metastasis.
NCT03898908 ↗ Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain Not yet recruiting Pierre Fabre Medicament Phase 2 2019-05-01 Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain. Cohort 1 will include patients with asymptomatic brain metastases and cohort 2 will include patients with symptomatic brain metastasis.
NCT03898908 ↗ Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain Not yet recruiting Grupo EspaƱol Multidisciplinar de Melanoma Phase 2 2019-05-01 Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain. Cohort 1 will include patients with asymptomatic brain metastases and cohort 2 will include patients with symptomatic brain metastasis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Braftovi

Condition Name

Condition Name for Braftovi
Intervention Trials
Metastatic Rectal Adenocarcinoma 2
Metastatic Colon Adenocarcinoma 2
Metastatic Microsatellite Stable Colorectal Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Braftovi
Intervention Trials
Melanoma 5
Carcinoma 3
Adenocarcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Braftovi

Trials by Country

Trials by Country for Braftovi
Location Trials
Spain 6
United States 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Braftovi
Location Trials
California 2
Maryland 1
Oregon 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Braftovi

Clinical Trial Phase

Clinical Trial Phase for Braftovi
Clinical Trial Phase Trials
Phase 3 1
Phase 2 6
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Braftovi
Clinical Trial Phase Trials
Not yet recruiting 8
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Braftovi

Sponsor Name

Sponsor Name for Braftovi
Sponsor Trials
National Cancer Institute (NCI) 5
EADO - European Association of Dermato Oncology 1
Pfizer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Braftovi
Sponsor Trials
Other 11
NIH 5
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Express Scripts
Colorcon
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.